Harvard Bioscience (NASDAQ:HBIO) Stock Rating Upgraded by Wall Street Zen

Harvard Bioscience (NASDAQ:HBIO) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

HBIO has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harvard Bioscience in a research report on Wednesday, October 8th. Benchmark lowered their price target on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating on the stock in a report on Wednesday, September 10th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Harvard Bioscience presently has a consensus rating of “Hold” and an average target price of $2.00.

Harvard Bioscience Stock Performance

Shares of Harvard Bioscience stock opened at $0.64 on Monday. The stock’s fifty day moving average is $0.48 and its 200 day moving average is $0.46. Harvard Bioscience has a one year low of $0.28 and a one year high of $2.40. The stock has a market cap of $28.55 million, a P/E ratio of -0.49 and a beta of 1.60.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HBIO. Two Sigma Investments LP grew its holdings in Harvard Bioscience by 139.7% during the 3rd quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock valued at $208,000 after buying an additional 276,372 shares in the last quarter. Williams & Novak LLC boosted its position in shares of Harvard Bioscience by 158.5% during the third quarter. Williams & Novak LLC now owns 275,500 shares of the medical instruments supplier’s stock worth $121,000 after acquiring an additional 168,930 shares during the last quarter. AMH Equity Ltd grew its stake in Harvard Bioscience by 15.4% during the third quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock valued at $1,775,000 after acquiring an additional 538,832 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Harvard Bioscience by 278.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 139,220 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 102,419 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Harvard Bioscience by 491.9% during the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares during the last quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.